A Study of ABT-751 in Patients With Colorectal Cancer
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Colorectal Cancer
DRUG: ABT-751
Objective Response Rate in subjects with Recurrent Colorectal Cancer, 1 year
Time to Tumor Progression (TTP), 1 year|Survival, 2 years|Toxicities associated with treatment administration, 1 year
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.